share_log

Personalis Shares Are Trading Higher After the Company and Moderna Recently Announced a Multi-year Extension to Continue Utilizing the Personalis ImmunoID NeXT Platform and Technology for V940/mRNA-4157. The Company Also Announced an Investment From...

Personalis Shares Are Trading Higher After the Company and Moderna Recently Announced a Multi-year Extension to Continue Utilizing the Personalis ImmunoID NeXT Platform and Technology for V940/mRNA-4157. The Company Also Announced an Investment From...

Personalis的股票在公司與Moderna最近宣佈繼續使用Personalis ImmunoID NeXt平台和科技用於V940/mRNA-4157的多年擴展後開始上漲。公司還宣佈了一項投資來自...
Benzinga ·  15:29

Personalis Shares Are Trading Higher After the Company and Moderna Recently Announced a Multi-year Extension to Continue Utilizing the Personalis ImmunoID NeXT Platform and Technology for V940/mRNA-4157. The Company Also Announced an Investment From Merck.

Personalis的股票在公司與Moderna最近宣佈與Personalis ImmunoID NeXt平台及科技繼續合作的多年度延續後上漲。此外,公司還宣佈了來自默沙東的投資。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論